Sign in Sign up for free

Last updated: 19 February 2020 at 5:17pm EST

Charles York Net Worth




The estimated Net Worth of Charles N Ii York is at least $1.5 Million dollars as of 1 December 2017. Mr. York owns over 25,959 units of Aeglea BioTherapeutics Inc stock worth over $417,792 and over the last 9 years he sold AGLE stock worth over $0. In addition, he makes $1,085,140 as Chief Financial Officer and Vice President at Aeglea BioTherapeutics Inc.

Mr. York AGLE stock SEC Form 4 insiders trading

Charles has made over 1 trades of the Aeglea BioTherapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 25,959 units of AGLE stock worth $116,296 on 1 December 2017.

The largest trade he's ever made was buying 25,959 units of Aeglea BioTherapeutics Inc stock on 1 December 2017 worth over $116,296. On average, Charles trades about 3,245 units every 0 days since 2016. As of 1 December 2017 he still owns at least 34,787 units of Aeglea BioTherapeutics Inc stock.

You can see the complete history of Mr. York stock trades at the bottom of the page.





Charles York biography

Charles N. York II, CPA serves as Chief Financial Officer, Vice President of the Company. Prior to joining Aeglea, Mr. York served as CFO Consultant of Bridgepoint Consulting, a finance consulting company, where he focused on life science, pharmaceutical and healthcare companies, from March 2013 to June 2014. From March 2009 to August 2012, Mr. York was the corporate controller of Astrotech Corporation. Prior to that, Mr. York held financial management roles at Arthrocare Corp. and Freescale Semiconductor Inc. Mr. York began his career at PricewaterhouseCoopers LLP. Mr. York is a CPA in the state of Arizona and received a B.S. in Accounting from the University of Connecticut and an MBA from the McCombs School of Business at the University of Texas at Austin.

What is the salary of Charles York?

As the Chief Financial Officer and Vice President of Aeglea BioTherapeutics Inc, the total compensation of Charles York at Aeglea BioTherapeutics Inc is $1,085,140. There are 2 executives at Aeglea BioTherapeutics Inc getting paid more, with Anthony Quinn having the highest compensation of $2,482,780.



How old is Charles York?

Charles York is 42, he's been the Chief Financial Officer and Vice President of Aeglea BioTherapeutics Inc since 2015. There are 15 older and no younger executives at Aeglea BioTherapeutics Inc. The oldest executive at Aeglea BioTherapeutics Inc is V. Bryan Lawlis, 68, who is the Independent Director.

What's Charles York's mailing address?

Charles's mailing address filed with the SEC is C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN, TX, 78746.

Insiders trading at Aeglea BioTherapeutics Inc

Over the last 9 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag..., and Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.



What does Aeglea BioTherapeutics Inc do?

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f



What does Aeglea BioTherapeutics Inc's logo look like?

Aeglea BioTherapeutics Inc logo

Complete history of Mr. York stock trades at Aeglea BioTherapeutics Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
1 Dec 2017 AGLE Aeglea BioTherapeutics Inc Charles N Ii York
Chief Financial Officer and Vice President
 Buy 25,959 $4.48 $116,296
1 Dec 2017
34,787 ↗


Aeglea BioTherapeutics Inc executives and stock owners

Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include: